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Hyper-IgM syndrome type 1 (HIGM1) is a primary immunodeficiency characterized by recurrent bacterial and opportunistic infections,
associated with normal or high serum level of IgM and decreased serum levels of IgG, IgA and IgE due to the defect of class switch
recombination. CD40LG, located in Xq26, has been reported to be mutated in male HIGM1 patients. Here, we report the second case of a female
HIGM1 with the defect of CD40 ligand (CD40L) expression and of soluble serum CD40L. Clinical course and HIGM phenotype was
indistinguishable from that of male HIGM1 including severe neutropenia. High-resolution chromosome banding revealed that this patient’s
karyotype is 46, X, t(X;14)(q26.3;q13.1), and FISH analysis demonstrated that the break point of the chromosomal translocation is within
CD40LG. Using four chimeric cDNA clones obtained by 3V RACE method, the break point was identified within the intron 4 of CD40LG on X
chromosome and non-coding region of chromosome 14. We also found an extremely skewed X-chromosome inactivation pattern by methylation-
specific PCR. Thus, the reciprocal translocation caused the disruption of CD40LG, resulting in defective CD40L expression in the female patient
with an extremely skewed X-inactivation pattern in T cells leading to the HIGM1 phenotype.
D 2005 Elsevier B.V. All rights reserved.Keywords: Primary Immunodeficiency; B lymphocyte; T lymphocyte; CD40 ligand; Balanced translocation; X-inactivation1. Introduction
Hyper-IgM syndrome (HIGM) is a primary immunodefi-
ciency syndrome characterized by recurrent bacterial infections
associated with low serum IgG, IgA and IgE due to the defect
of class switch recombination (CSR) of immunoglobulin genes
[1]. Several molecular defects were found to be responsible for
this syndrome. Hyper-IgM syndrome type 1 (HIGM1) was
found to be due to mutations in the CD40 ligand (CD40L,
CD154) [2–5]. CD40L is encoded by the gene CD40LG which0925-4439/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2005.10.003
Abbreviations: HIGM, hyper-IgM syndrome; CD40LG, CD40 ligand;
CD40-Ig, human CD40 coupled with the Fc domain of human IgG1
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E-mail address: nonoyama@ndmc.ac.jp (S. Nonoyama).is located on the X chromosome. CD40L is expressed on the
surface of the activated T cells and induces proliferation and
CSR to B cells. CD40L also activates dendritic cells through
CD40. Thus, defect of CD40L is associated not only with a
humoral immunodeficieny but also represents a combined
immunodeficiency characterized by opportunistic infections
with pathogens, such as Pneumocystis carinii or Cryptospo-
ridium pavium [6].
As CD40LG resides on the X chromosome and HIGM1 is
an X-linked recessive disease, most of the patients are male and
the female patients are asymptomatic carriers [7,8]. Here, we
report the second case of a female HIGM patient associated
with defective expression of CD40L on activated T cells due to
the translocation of X chromosome and chromosome 14
combined with skewed X chromosome inactivation.1762 (2006) 335 – 340
http://www
Table 1
Hyper-IgM syndrome phenotype of the patient
Patient Normal range
Serum IgM [mg/dl] 1335 54–106
Serum IgG [mg/dl] 169 530–1010
Serum IgA [mg/dl] 45 34–78
Serum IgE [IU/ml] <10 –
Proliferation* [cpm] 18,081T4961 36,574T8416
Switch to IgE** [pg/ml] 19,600T4850 18,377T6624
Soluble CD40L [ng/ml] 0 5–20
Proliferation*: Proliferation was analyzed by measuring the [3H] incorporating
activity after the stimulation of purified B cells with anti-CD40 monoclona
antibody and interleukin (IL)-4 for 5 days.
Switch to IgE**: Class switch to IgE was measured by ELISA measuring the
supernatants of the culture after the stimulation of purified B cells with anti
CD40 monoclonal antibody and interleukin (IL)-4 for 12 days.
Serum soluble CD40L was detected by ELISA as described previously [17].
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2.1. Monoclonal antibodies and reagents
We used monoclonal antibodies (mAb) against CD69 (Coulter Immunol-
ogy, Hialeah, FL), CD40 (G28-5) (kindly provided by Dr. Edward A. Clark,
Seattle, WA) and CD40L (1.7 and 106, gifts from Dr. A. Aruffo, Bristol-Myers
Squibb Pharmaceutical Research Institute, Princeton, NJ). A soluble fusion
protein consisting of the extracellular domain of human CD40 coupled with the
Fc domain of human IgG1 (CD40-Ig) was prepared as described previously [9].
FITC conjugated anti-mouse IgG (TAGO, Burlingame, CA) or FITC
conjugated anti-human IgG (TAGO) were used as a second antibody. Purified
human IL-4 was a gift from Dr. K. W. Moore (DNAX, Palo Alto, CA).
2.2. Patient and cell preparations
Heparinized blood was obtained simultaneously a female HIGM patient and
a normal control. Peripheral blood lymphocytes (PBL) were prepared by Ficoll-
Hypaque gradient centrifugation. To further purify B cells, T cells were
removed from PBL by twice rosetting with aminoethylisothiuronium bromide
(AET) (Sigma Chemical Co., St. Louis MO) treated sheep RBC [10]. NK cells
and monocytes were removed by treating the B cell enriched cell suspension
with 5 mM l-leucine methyl ester hydrochloride (Sigma Chemical Co.) in
serum-free RPMI 1640 as described [10]. The final cell preparation consisted of
>90% B cells (CD20+) and <1% T cells (CD3+) as determined by flow
cytometry.
This study was carried out in accordance with the Declaration of Helsinki
and was approved by the institutional ethics committee. Informed consent was
obtained from the parents of the patient before the study.
2.3. CD40 ligand expression
Freshly-isolated PBL at 1106 cells/ml were cultured in RPMI 1640
supplemented with 10% FCS (Hyclone, Logan, UT), 2 mM glutamine
(complete medium) with or without phorbol 12-myristate 13-acetate (PMA, 10
ng/ml) and ionomycin (1 Ag/ml). After 8 h of culture, cells were washed and
resuspended in RPMI containing 2% fetal calf serum, and stained with 25 Ag/
ml of CD40-Ig or cL6, an isotype matched fusion protein as described
previously [10]. After washing, cells were incubated with FITC conjugated
goat anti-human IgG for 30 min at 4 -C. Fusion protein binding was deter-
mined by FACScan (Becton Dickinson, Mountainview, CA). Percentages of
positively stained cells were calculated by subtracting the total fluorescence
intensity of cells stained with the isotype matched fusion protein (cL6). In
some experiments, activated PBL were stained with anti-CD40L mAbs 1.7
and 106, respectively, and FITC conjugated anti human-IgG as a second
antibody.
2.4. Stimulation of B cells with anti-CD40 mAb and IL-4
To induce B cell proliferation, 2.5104 purified B cells were cultured for 4
days in 96-well flat bottom microculture plates at a final volume of 200 Al of
complete medium with anti-CD40 mAb G28-5 (1 Ag/ml) and IL-4 (100 U/ml)
followed by a 16-h pulse with 1 ACi [3H] thymidine. To induce IgE production,
2.5104 purified B cells per well were cultured in 96-well round bottom
microculture plates in 200 Al of complete medium in the presence of mAb G28-
5 (1 Ag/ml) and IL-4 (100 U/ml). After 12 days of culture, supernatants were
collected and tested for IgE concentrations by ELISA as described previously
[10].
2.5. Fluorescence in situ hybridization
The procedure of fluorescence in situ hybridization (FISH) has been
described elsewhere [11]. Three DNA probes, probe A (13 kb), probe B
(10 kb) and probe C (30 kb), which span different sites of CD40LG as shown
in Fig. 3A were used. Probes were labeled by a nick translation system
(Roche Diagnostics, Basel, Switzerland) using digoxigenin-11-dUTP (Roche
Diagnostics). After stopping the labeling process by heating (65 -C, 10 min),the labeled probes were purified by ethanol precipitation using 4M
CH3COONH4, 100% ethanol, salmon sperm DNA (10 mg/ml), and E. coli.
tRNA (19 mg/ml, Sigma). For the elimination of non-specific hybridization
with repetitive sequences, a suppression hybridization procedure with human
Cot-1 DNA was applied [11]. Human Cot-1 DNA (10 mg/ml, Invitrogen,
Carlsbad, CA) in formamide was added to the DNA probe, and then
denatured at 75 -C for 10 min. Hybridization solution consisting of 20%
dextran sulfate, 4 SSC and bovine serum albumin (BSA, 4 mg/ml) was
added to the probe DNA, and then applied on the denatured chromosomes.
The chromosomes were stained with anti-digoxigenin fluorescein (1.6 Ag/ml,
Roche Diagnostics), and then counterstained with 0.5 mg/ml propidium
iodide (Sigma). Pictures were taken by microphotography using a Nikon B-
2A filter.
2.6. Identification of the break point in CD40LG
PBL obtained from the patient were activated with PMA and ionomycin for
2 h. Total RNA was isolated by the Acid Guanidium-Phenol-Chloroform
(AGPC) method. Complementary DNA (cDNA) was synthesized from total
RNA with Super Script (Invitrogen) using QT primer (5V-CCAGTGAGCA-
GAGTGACGAGGACTCGAGCTCAAGCTTTTTTTTTTTTTTTTT), and
rapid amplification of cDNA ends (RACE) method was performed to obtain
the 3V end of the cDNA as described previously [12]. Two nested primers
corresponding to nucleotides 151–170 (5V-GTGTATCTTCATAGAAGGTT,
primer 383) and 344–363 (5V-AAAACAGCTTTGAAATGCAA, primer 385)
of CD40LG cDNA were used along with QO primer (5V-CCAGTGAGCA-
GAGTGACG) and QI primer (5V-GAGGACTCGAGCTCAAGC) [12]. PCR
products were subcloned into pT7Blue T Vector (Novagen, Madison, WI), and
sequenced. Four different cDNA clones, A, B, C, and D as shown in Fig. 3
were obtained. Genomic DNA of the patient was amplified by PCR using
primer A (5V-CAGTTGTAGAACTGGACCAG) corresponding to the nucleo-
tides in intron 3 of CD40LG [13] and primer B corresponding to the nucleotide
sequence of clone A as shown in Fig. 4. PCR conditions were identical to those
described previously [13]. The PCR product was subcloned into pT7Blue T
Vector, and sequenced. Sequence was performed by the dideoxy chain
termination method with a Model 373A Automated DNA sequencer (Applied
Biosystems, Foster City, CA).
3. Results
3.1. Defective CD40 ligand expression on activated PBL of a
female HIGM patient
At diagnosis, the patient was 1 year old, presenting with
recurrent bacterial upper and lower respiratory tract infections
and abnormal serum immunoglobulin levels (Table 1). She hadl
-
Fig. 1. CD40 ligand expression was defective on activated PBL obtained from a female HIGM patient. Peripheral blood lymphocytes (PBL) obtained from a female
HIGM patient in this report (right panels), a HIGM type 2 with the recessive mutation of AICDA (center panels) and an age-matched healthy donor (left panels), were
cultured with PMA (10 ng/ml) and ionomycin (1 Ag/ml) for 8 h, then stained with CD40-Ig (shaded curve) or with cL6 as a control fusion protein (open curve)
followed by FITC conjugated anti-human IgG. To demonstrate the activation of cells, the samples were simultaneously stained with PE-conjugated anti-CD69
(shaded curve) or with PE-conjugated mouse IgG (open curve). The numbers in the figures indicate the percent positivity induced by the addition of PMA and
ionomycin.
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Al at diagnosis). No other anomalies were found. The parents
were non-consanguineous and healthy.
The patient’s B cells proliferated normally and produced
normal amounts of IgE in response to anti-CD40 and IL-4 as
seen in normal controls indicating normal CSR ability of the
patient B cells (Table 1).
Although the patient was a girl, her hyper-IgM syndrome
(HIGM) phenotype associated with neutropenia and normal in
vitro CSR activity of B cells led us to test the expression of
CD40 ligand (CD40L) on activated T cells. CD40L expression,
detected by either CD40-Ig (Fig. 1) or anti-CD40L mAbs 1.7
and 106 (data not shown), was defective after the stimulation of
PMA and ionomycin. CD69, an early activation marker, was
expressed normally on activated PBL of the patient and normal
controls indicating the defect of CD40L expression was not
due to the defect of activation (Fig. 1). Furthermore, soluble
serum CD40L (sCD40L) was not detected indicating the lack
of CD40L expression in vivo (Table 1).Fig. 2. Partial karyotype of the balanced translo3.2. Analysis of CD40LG in a female HIGM patient with
defective CD40L expression
G-banding of patient chromosomes revealed a reciprocal
translocation between chromosome X and chromosome 14
(data not shown). This translocation is sporadic as the parents
had normal karyotypes. High-resolution chromosome banding
demonstrated the patient’s karyotype of 46, X, t(X;14) (q26.3;
q13.1) (Fig. 2).
Therefore, the translocation could disrupt CD40LG, the
gene coding for CD40L, located at Xq26.3. FISH analysis was
performed using three different probes (probe A: 13 kbp, 5V
untranslated region (UT)—Intron 2, B: 10 kbp, intron 2—Exon
5 and C: 30 kbp, intron 2—3VUT), which span the different
parts of CD40LG as indicated in Fig. 3A. Probe A (Fig. 3B)
and probe B (Fig. 3C) hybridized with CD40LG on the normal
X and the derivative X chromosomes but not with the
derivative chromosome 14. In contrast, probe C (Fig. 3D)
hybridized with the normal and derivative X chromosomes andcation t(X;14)(q26.3;q13.1) of the patient.
Fig. 3. FISH analysis of the chromosomes of the patient. (A) Probes used for FISH analysis. Three different probes were used for the FISH analysis. Probe A (13
kbp), and probe B (10 kbp) and probe C (30 kbp) cover different sites of CD40LG genomic region. The five exons of CD40LG are shown as boxes. E: EcoRI site, B:
BamHI site. (B–D) Results of FISH analysis. FISH analysis was performed using probes A–C and chromosome preparations from the patient with the karyotype of
46, X, t(X;14) (q26.3; q13.1). (B) and (C) Hybridized with normal and derivative X chromosomes (white arrows), but failed to hybridize with derivative 14
chromosome. (D) Probe C hybridized with normal X chromosome (white arrow), derivative X chromosome (blue arrowhead) and derivative chromosome 14 (white
arrowhead).
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CD40LG was disrupted by the reciprocal translocation between
chromosome X and chromosome 14, and that the 5V part of the
disrupted CD40LG is on the derivative X chromosome and the
3V part is on the derivative chromosome 14.
To define the break point of CD40LG in this patient, we
isolated total RNA from PMA and ionomycin activated
lymphocytes and generated cDNA. Since FISH analysis
indicated that the break point is likely located at the 3V portion
of CD40LG, we performed the 3V-RACE technique. Sequence
analysis of the cDNA clones obtained by the RACE method
identified four different cDNA clones (clone A: 5 clones, B: 5
clones, C: 8 clones, D: 1 clones). Three types of clones (A, B,
C) consisted of normal exon 1, 2, 3 and 4 of CD40LG followed
by three unknown sequences as shown in Fig. 4.Fig. 4. cDNA clones containing CD40LG obtained from the patient. The RACE met
cDNA was synthesized from total RNA isolated from activated patient PBL. Nested
Materials and methods), and PCR products were subcloned into the TA cloning vec
contained a normal exon 4 followed by undefined sequences. In clone D, exon 4
designed corresponding to the nucleotide sequence in clone A as shown in the figuThe BLAST analysis on NCBI site revealed that these
unknown sequences are situated on chromosome 14q13.2 where
neither protein-coding gene nor EST has been reported. The
sequence from clone A is the most centromeric region and the
sequence from clone C is the most telomeric region (A: 6938th
nucleotide, B: 26518th nucleotide, C: 48794th nucleotide on
AL049776.3). In the clone D, a normal exon 5 of CD40LG
followed directly after the 3V end of exon 4, indicating that this
clone was derived from the normal X chromosome. To clarify
the breakpoint, we amplified genomic DNA of the patient using
primer A, which corresponds to the sequence of intron 3 of
CD40LG and primer B, which corresponds to the nucleotides in
clone A as shown in Fig. 4. The PCR product was subcloned and
sequenced. As shown in Fig. 5, the genomic DNA obtained has a
normal CD40LG exon 4 sequence, part of the normal CD40LGhod was performed to determine the 3V end of exon 4 of CD40LG in the patient.
PCR was performed using two sets of primers (383 and QO, 385 and QI, see
tors, and sequenced. Four different clones (A–D) were identified. Clones A–C
was followed by a normal exon 5. To amplify genomic DNA, primer B was
re.
Fig. 5. Sequence analysis of genomic DNA of the patient. Genomic DNA
obtained from the patient was amplified by PCR using the specific primer A
(corresponding to nucleotides within intron 3, see Materials and methods) and
primer B. PCR product was subcloned into the TA cloning vector and
sequenced. The break point of CD40LG caused by chromosome translocation
is shown by an arrow. The break point is located within intron 4 of CD40LG.
The sequence found in clone A (Fig. 4) is boxed.
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to the sequence of clone A.
The sequence between breakpoint and the sequence of clone
A is also on chromosome 14q13.2. Thus, the break point of
CD40LG in this patient was located within intron 4 of
CD40LG. This result indicates that the cDNA clone A was
produced by RNA splicing using the 5V donor splice site of
intron 4 of CD40LG and the cryptic acceptor splice site located
within the genomic DNA translocated from chromosome 14.
Clone B and clone C may be produced by alternative splicing
of the chimeric CD40LG RNA. Carriers with a heterozygous
mutation of CD40LG usually have no phenotype [14] but one
female patient with heterozygous mutation of CD40LG due to
a skewed pattern of X chromosome inactivation was reported
[15] although our patient had more severe phenotype. Thus we
performed methylation-specific PCR to analyze X chromosome
inactivation. We found that the normal X chromosome was
active only in ¨3% of the cells as previously reported [16].
These results indicate that this patient’s HIGM phenotypes are
caused by disrupted CD40LG due to a balanced translocation
between Xq26.3 and 14q14.2 with an extremely skewed X
inactivation pattern in which the intact CD40LG on the normal
X chromosome is extensively inactivated.
4. Discussion
In this study, we found one female HIGM patient with normal
B cell responses after CD40 crosslinking in vivo, but the lack of
CD40L expression after the activation of T cells. HIGM type 1
(HIGM1) due to mutations in CD40LG is an X-linked recessive
disease and female carriers of the patients usually do not have a
HIGM phenotype [6]. Only one female carrier of HIGM1, with
heterozygous nonsense mutation of CD40LG (Q118X) was
reported to have CD40L expression deficiency due to skewed
lyonization. The case which had recurrent bacterial upper
respiratory infections with low serum IgA (11 mg/dl) and IgG
(620mg/dl) and normal IgM (73mg/dl) without neutropenia and
opportunistic infections was milder than our case. No karyotypic
abnormalities were found in this patient [15].
We performed karyotype and FISH analyses of the female
patient and found that one of two X chromosomes had atranslocation to chromosome 14 in which CD40LG was
disrupted (46,X,t(X;14)(q26.3;q13.1)). We further found that
the break point of this translocation to be in intron 4 of
CD40LG. The product of this disrupted gene would result in
truncated CD40L molecule that lacks exon 5, which is
responsible for the TNF homology domain of CD40L. The
TNF homology domain plays an important role in the
interaction with CD40 and its absence will result in a
nonfunctional CD40L molecule.
As a result of this translocation, each of the patient’s cells
has one normal X chromosome and one derivative X
chromosome with a disrupted CD40LG, and a translocated
distal part of the long arm to chromosome 14. Cells with the
normal active X chromosome should have the inactivated
defective X chromosome. Thus, a skewed inactivation of the
defective X chromosome is expected in this patient. Consistent
with this hypothesis is the finding that of 19 clones obtained
by 3V RACE, only one was found to have a normal exon 5
sequence of CD40LG. In contrast, the other clones transcribed
from the derivative X chromosome were represented frequent-
ly. These results were supported by the flowcytometric pattern
in the present study, in which the expression of CD40L in the
stimulated cells was less than 3%, and further supported by the
previously reported X-inactivation pattern of this patients, in
which the normal X chromosome is active only in ¨3% of the
cells [16]. This extremely skewed X-inactivation pattern was
consistent with the X;autosome balanced translocation. To
avoid inactivating the translocated long arm of chromosome 14
leading to 14q monosomy, the autosome-translocated X
chromosome is activated and the normal X chromosome is
inactivated. Thus, it is highly likely that this phenomenon in
our patient suppresses the intact CD40LG expression on the
normal X and activates the disrupted CD40LG expression on
the translocated X, resulting in the patient’s HIGM phenotype.
Since our patient showed a typical HIGM phenotype indistin-
guishable from that of male HIGM1 without any other
anomalies, the effect of the X;14 translocation seemed to be
only disruption of CD40LG. Thus, other female patients with
HIGM may have similar abnormal structural and functional
karyotype abnormalities. Therefore, it may be necessary to
perform a karyotype analysis as well as mutation for CD40LG
in female patients with HIGM with defective expression of
CD40L.
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